Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
t6A and ms2t6A Modified Nucleosides in Serum and Urine as Strong Candidate Biomarkers of COVID-19 Infection and Severity.
Nagayoshi Y, Nishiguchi K, Yamamura R, Chujo T, Oshiumi H, Nagata H, Kaneko H, Yamamoto K, Nakata H, Sakakida K, Kunisawa A, Adachi M, Kakizoe Y, Mizobe T, Kuratsu JI, Shimada S, Nakamori Y, Matsuoka M, Mukoyama M, Wei FY, Tomizawa K. Nagayoshi Y, et al. Biomolecules. 2022 Sep 3;12(9):1233. doi: 10.3390/biom12091233. Biomolecules. 2022. PMID: 36139072 Free PMC article.
Camostat mesilate, a serine protease inhibitor, exerts aquaretic effects and decreases urinary exosomal AQP2 levels.
Kakizoe Y, Nakagawa T, Iwata Y, Deng Q, Adachi M, Miyasato Y, Nakagawa M, Nagayoshi Y, Nishiguchi K, Narita Y, Izumi Y, Kuwabara T, Tomita K, Kitamura K, Mukoyama M. Kakizoe Y, et al. Among authors: nagayoshi y. J Pharmacol Sci. 2022 Dec;150(4):204-210. doi: 10.1016/j.jphs.2022.09.003. Epub 2022 Sep 19. J Pharmacol Sci. 2022. PMID: 36344042 Free article.
Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation.
Fujimoto D, Adachi M, Miyasato Y, Hata Y, Inoue H, Oda A, Kakizoe Y, Nakagawa T, Shimasaki A, Nakamura K, Nagayoshi Y, Mukoyama M. Fujimoto D, et al. Among authors: nagayoshi y. Clin Exp Nephrol. 2021 Feb;25(2):191-199. doi: 10.1007/s10157-020-01973-x. Epub 2020 Oct 6. Clin Exp Nephrol. 2021. PMID: 33025233 Free PMC article.
The serine protease plasmin plays detrimental roles in epithelial sodium channel activation and podocyte injury in Dahl salt-sensitive rats.
Deng Q, Kakizoe Y, Iwata Y, Nakagawa T, Miyasato Y, Nakagawa M, Nishiguchi K, Nagayoshi Y, Adachi M, Narita Y, Izumi Y, Kuwabara T, Tsuda Y, Mukoyama M. Deng Q, et al. Among authors: nagayoshi y. Hypertens Res. 2023 Jan;46(1):50-62. doi: 10.1038/s41440-022-01064-2. Epub 2022 Oct 15. Hypertens Res. 2023. PMID: 36241707
A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats.
Iwata Y, Deng Q, Kakizoe Y, Nakagawa T, Miyasato Y, Nakagawa M, Nishiguchi K, Nagayoshi Y, Narita Y, Izumi Y, Kuwabara T, Adachi M, Mukoyama M. Iwata Y, et al. Among authors: nagayoshi y. Int J Mol Sci. 2023 Oct 30;24(21):15743. doi: 10.3390/ijms242115743. Int J Mol Sci. 2023. PMID: 37958726 Free PMC article.
Autosomal dominant Alport syndrome due to a COL4A4 mutation with an additional ESPN variant detected by whole-exome analysis.
Izumi Y, Hamaguchi A, Miura R, Nakagawa T, Nakagawa M, Saida K, Miyake N, Nagayoshi Y, Kakizoe Y, Miyoshi T, Kohda Y, Misumi Y, Matsumoto N, Ando Y, Mukoyama M. Izumi Y, et al. Among authors: nagayoshi y. CEN Case Rep. 2020 Feb;9(1):59-64. doi: 10.1007/s13730-019-00429-w. Epub 2019 Nov 1. CEN Case Rep. 2020. PMID: 31677115 Free PMC article.